在这篇综述中，我们分析了晚期霍奇金淋巴瘤 (HL) 患者的不同治疗方案。晚期 HL 的治疗在过去十年中取得了很大进展，甚至仍然基于联合化疗。成熟的数据表明，更好的策略需要正电子发射断层扫描 (PET) 驱动的治疗，从而优化疾病控制与即时和后期治疗不良反应之间的平衡，从而治愈大多数患者，同时最大限度地降低毒性风险。事实上，PET 驱动的降级策略提供了更好的治疗选择。最近将靶向疗法、抗 CD30 或抗程序性细胞死亡蛋白 1 (PD1) 与化疗相结合，应该会迅速改变游戏规则，并在降低治疗毒性风险和提高治愈率方面向前迈出一步。目前晚期 HL 的护理标准仍然是 PET 驱动的化疗，并且应该随着靶向治疗与化疗相结合而迅速发展。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

In this review, we analyzed the different therapy options in patients with advanced Hodgkin lymphoma (HL).The treatment of advanced HL has greatly evolved during the last decade even still based on polychemotherapy. Mature data established that the better strategies require Positron emission tomography (PET)-driven treatments which allow to optimize the balance between disease control and both immediate and late treatment adverse effects, leading to cure most patients while minimizing the risk of toxicity. Indeed, PET-driven deescalated strategies offer the better treatment option. The recent incorporation of targeted therapies, anti-CD30 or anti-programmed cell death protein 1 (PD1) in combination with chemotherapy should quickly change the game and be a step forward to still decrease the risk of treatment toxicity and improve the cure rate.The standard of care for advanced HL remains currently PET-driven chemotherapy and should rapidly evolve with the addition of targeted therapy combined with chemotherapy.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.